Pre-made Palivizumab benchmark antibody ( Whole mAb, anti-RSV gpF therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-423
Pre-Made Palivizumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Palivizumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||2hwz:HL|
|95-98% SI Structure||None|
|Conditions Approved||Respiratory syncytial virus infections|
|Development Tech||GS Gene Expression System|